NRTX-1001 is being assessed for drug-resistant mesial temporal lobe epilepsy More: Neurona secures 0m to advance lead cell therapy candidate for epilepsy Source: News
read moreWith good news on Lybalvi, Alkermes sees 10% share price increase kdunleavy Thu, 02/15/2024 – 11:43 More: With good news on Lybalvi, Alkermes sees 10% share price increase Source: fierce
read moreAlnylam changes analysis plan for key Amvuttra heart trial, jolting investors aliu Thu, 02/15/2024 – 10:34 More: Alnylam changes analysis plan for key Amvuttra heart trial, jolting investors Source: fierce
read morePfizer quells 12 years of Lipitor antitrust litigation with $93M settlement zbecker Thu, 02/15/2024 – 10:28 More: Pfizer quells 12 years of Lipitor antitrust litigation with M settlement Source: fierce
read moreAs Catalent moves toward Novo buyout, its restructuring claimed 300 jobs last year fkansteiner Thu, 02/15/2024 – 08:48 More: As Catalent moves toward Novo buyout, its restructuring claimed 300 jobs last year Source: fierce
read moreFlorida CDMO New Vision Pharmaceuticals shutters plant, lays off 88 workers jkeenan Thu, 02/15/2024 – 08:09 More: Florida CDMO New Vision Pharmaceuticals shutters plant, lays off 88 workers Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals